Showing 1811-1820 of 2657 results for "".
- Allergan Presents Data at the ARVO Annual Meeting in Honoluluhttps://modernod.com/news/allergan-presents-data-at-the-arvo-annual-meeting-in-honolulu/2480202/Allergan announced that 19 posters on their eye care offerings will be presented at this year’s ARVO meeting in Hawaii. These presentations will cover a variety of topics in various subspecialties, including ocular surface, glaucoma, and retina. Retina Post
- Zeiss Presents Diagnostic and Surgical Advancements at ASCRShttps://modernod.com/news/zeiss-presents-diagnostic-and-surgical-advancements-at-ascrs/2480244/Zeiss will present its latest ophthalmic diagnostic and surgical advancements at the 2018 American Society of Cataract and Refractive Surgery’s Annual Meeting taking place April 13-17 in Washington DC. Zeiss will also be hosting
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- National Eye Institute Selects Richard Lee, MD, PhD, as Clinical Directorhttps://modernod.com/news/national-eye-institute-selects-richard-lee-md-phd-as-clinical-director/2481999/The National Eye Institute (NEI) has chosen Richard Lee, MD, PhD, as the institute’s clinical director, overseeing clinical research and serving as clinical policy advisor for NEI. Dr. Lee comes to NEI from Moorfields Eye Hospital, where he’s had several roles since 2011, th
- EverSight Launches Preloaded DMEK EndoGlidehttps://modernod.com/news/eversight-launches-preloaded-dmek-endoglide-1/2481517/Nonprofit eye bank Eversight announced the availability of Descemet’s membrane endothelial keratoplasty (DMEK) tissue preloaded in EndoGlide, offering corneal surgeons a fourth preloaded DMEK option to further s
- Dompé Announces First Patient Enrolled in Phase 3 Trial of Cenegermin in Patients With Severe Sjögren's-Related Dry Eye Diseasehttps://modernod.com/news/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2480630/Dompé announced that the first patient has been enrolled in its phase 3 clinical trial to evaluate the efficacy and safety of cenegermin in patients with severe Sjögren's-related dry eye disease, a primary symptom of Sjögren's. This trial is part of a program th
- Korean Ophthalmologist Oh Jungwoo Performs “25 Sec LASEK” in Public for the First Timehttps://modernod.com/news/korean-ophthalmologist-oh-jungwoo-performs-25-sec-lasek-in-public-for-the-first-time/2477147/Dr. Oh Jungwoo from Eos Eye Center in Gangnam-gu, Korea, revealed a “25 sec LASEK” surgery publicly by video. This is the first time the operation has been released to the public and it shows Dr. Oh’s surgery on a patient’s left eye with minimal corneal damage in 25 second
- Exploring a Connection Between GLP-1 Drugs and Vision Losshttps://modernod.com/news/exploring-a-connection-between-glp-1-drugs-and-vision-loss/2484306/Two studies presented at the 2025 AAO Annual Meeting explored a possible connection between GLP-1 drugs and vision loss. Using data from the World Health Organization’s global database of drug safety reports, researchers at the University of Ottawa Eye Institute, University of Tor
- Viridian Submits BLA for Veligrotug in Thyroid Eye Diseasehttps://modernod.com/news/viridian-submits-bla-for-veligrotug-in-thyroid-eye-disease/2484303/Viridian Therapeutics has submitted a Biologics License Application (BLA) to the FDA for veligrotug, the company’s investigational therapy for thyroid eye disease (TED). The submission, completed in October, follows positive results from two pivotal phase 3 trials, THRIVE and THRIVE-2, that
- Novartis Announces Positive Phase 3 Results for Ianalumab in Sjögren’s Diseasehttps://modernod.com/news/novartis-announces-positive-phase-3-results-for-ianalumab-in-sjogrens-disease/2484297/Novartis announced new late-breaking data from the NEPTUNUS-1 and NEPTUNUS-2 phase 3 trials evaluating ianalumab in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease. The results, presented during the American College of Rheumatol